A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality

References

• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Gupta S, Cantor J, Simon KI, et al. Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. Health Aff (Millwood). 2021 Sep;40(9):1465–1472. doi:https://doi.org/10.1377/hlthaff.2021.00619. Epub 2021 Aug 18. PMID: 34406840.
   PubMed Web of Science ®Google Scholar
• Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020 Nov 1;180(11):1436–1447.
   PubMed Web of Science ®Google Scholar
• McCormick KD, Jacobs JL, Mellors JW. The emerging plasticity of SARS-CoV-2. Science. 2021;371(6536):1306–1308.
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818.
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of Lopinavir/Ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672–683.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Guérin V, Lévy P, Thomas JL, et al. Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19. Asian J Med Health. 2020;18(7):45–55.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 – final report. N Engl J Med. 2020 Nov 5;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Aumpan N, Vilaichone RK, Ratana-Amornpin S, et al. Antiviral treatment could not provide clinical benefit in management of mild COVID-19: a retrospective experience from field hospital. J Infect Public Health. 2021;14(9):1206–1211.
   Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• Lopez-Medina E, Lopez P, Hurtado IC, et al. Effect of Ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):1426–1435.
   PubMed Web of Science ®Google Scholar
• Mitja O, Corbacho-Monne M, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of covid-19. N Engl J Med. 2021;384(5):417–427.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021 Feb 16;325(7):632–644.
   PubMed Web of Science ®Google Scholar
• Libster R, Perez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. 2021;384(7):610–618.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384(3):238–251.
   PubMed Web of Science ®Google Scholar
• Zoufaly A, Poglitsch M, Aberle JH, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8:1154–1158.
   PubMed Web of Science ®Google Scholar
• Ansarin K, Tolouian R, Ardalan M, et al. Effect of Bromhexine on clinical outcomes and mortality in COVID-19 patients: a randomized clinical trial. Bioimpacts. 2020;10(4):209–215.
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020 Nov 19;383(21):2030–2040.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020 Nov 19;383(21):2041–2052.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 24;396(10259):1345–1352.
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci. 2020 Feb 1;157:105631.
   Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470.
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629.
   PubMed Web of Science ®Google Scholar
• Chu CM, Poon LL, Cheng VC, et al. Initial viral load and the outcomes of SARS. CMAJ. 2004;171(11):1349–1352.
   PubMed Web of Science ®Google Scholar
• Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. Br Med J. 2020;369:m1443.
   PubMed Web of Science ®Google Scholar
• Yu X, Sun S, Shi Y, et al. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Crit Care. 2020;24(1):170.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656–657.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis. 2020 Jun 30;ciaa851.
   PubMed Web of Science ®Google Scholar
• Shi F, Wu T, Zhu X, et al. Association of viral load with serum biomarkers among COVID-19 cases. Virology. 2020;546:122–126.
   PubMed Web of Science ®Google Scholar
• To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574.
   PubMed Web of Science ®Google Scholar
• Tan L, Kang X, Ji X, et al. Validation of predictors of disease severity and outcomes in COVID-19 patients: a descriptive and retrospective study. Med (N Y). 2020 Dec 18;1(1):128–138.e3.
   Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, et al. Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(6):1294–1297.
   PubMed Web of Science ®Google Scholar
• Alam S, Kamal TB, Sarker MMR, et al. Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021. Front Pharmacol. 2021;12:659577.
   Web of Science ®Google Scholar
• Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325(12):1185–1195.
   PubMed Web of Science ®Google Scholar
• Liao J, Way G, Madahar V. Target virus or target ourselves for COVID-19 drugs discovery? Lessons learned from anti-influenza virus therapies. Med Drug Discov. 2020;5:100037.
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• van der Wijst MGP, Vazquez SE, Hartoularos GC, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021 Sep 22;13(612):eabh2624.
   Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585.
   PubMed Web of Science ®Google Scholar
• Moreno-Eutimio MA, Lopez-Macias C, Pastelin-Palacios R. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect. 2020;22(4–5):226–229.
   PubMed Web of Science ®Google Scholar
• Cunha LL, Perazzio SF, Azzi J, et al. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. Front Immunol. 2020;11:1748.
   PubMed Web of Science ®Google Scholar
• Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany, NY). 2020;12(10):9959–9981.
   PubMedGoogle Scholar
• Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021 Aug 10;326(6):499–518.
   PubMed Web of Science ®Google Scholar
• Mariette X, Hermine O, Tharaux PL, et al. Effectiveness of Tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern Med. 2021;181(9):1241–1243.
   PubMed Web of Science ®Google Scholar
• Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020 Dec;8(12):1233–1244.
   PubMed Web of Science ®Google Scholar
• Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92(7):856–862.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Larcher A, Tomelleri A, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021;3(4):e253–ee61.
   PubMedGoogle Scholar
• Franzetti M, Forastieri A, Borsa N, et al. IL-1 receptor antagonist Anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study. J Immunol. 2021;206(7):1569–1575.
   PubMed Web of Science ®Google Scholar
• Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021 May;10(5):660–673.
   PubMed Web of Science ®Google Scholar
• Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19 – preliminary report. N Engl J Med. 2020 Feb 25;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–1454.
   PubMed Web of Science ®Google Scholar
• Penaloza HF, Lee JS, Ray P. Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease. PLoS Pathog. 2021;17(9):e1009850.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Feng Z, Diao B, et al. SARS-CoV-2 induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs. Front Immunol. 2021;12:661052.
   PubMed Web of Science ®Google Scholar
• Casucci G, Acanfora D, Incalzi RA. The cross-talk between age, hypertension and inflammation in COVID-19 patients: therapeutic targets. Drugs Aging. 2020;37(11):779–785.
   Web of Science ®Google Scholar
• Assersen KB, Sumners C, Steckelings UM. The renin-angiotensin system in hypertension, a constantly renewing classic: focus on the angiotensin AT2-receptor. Can J Cardiol. 2020;36(5):683–693.
   Web of Science ®Google Scholar
• Saravi B, Li Z, Lang CN, et al. The tissue renin-angiotensin system and its role in the pathogenesis of major human diseases: Quo vadis? Cells. 2021 Mar 15;10(3):650.
   PubMed Web of Science ®Google Scholar
• Rysz S, Al-Saadi J, Sjostrom A, et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. Nat Commun. 2021;12(1):2417.
   PubMed Web of Science ®Google Scholar
• Latil M, Camelo S, Veillet S, et al. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients. Drug Discov Today. 2021 May;26(5):1311–1318.
   Web of Science ®Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374.
   PubMed Web of Science ®Google Scholar
• Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020;46(6):1105–1108.
   PubMed Web of Science ®Google Scholar
• Muslim S, Nasrin N, Alotaibi FO, et al. Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE2, angiotensin (1–7) and angiotensin (1–9) as effective therapeutic measure. SN Compr Clin Med. 2020 Aug 22; 1–6.
   Google Scholar
• Wu Z, Hu R, Zhang C, et al. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit Care. 2020;24(1):290.
   Web of Science ®Google Scholar
• Henry BM, Benoit J, Berger B, et al. Coronavirus disease 2019 (COVID-19) is associated with low circulating plasma levels of angiotensin 1 and angiotensin 1,7. J Med Virol. 2020 Feb;93(2):678–680.
   Web of Science ®Google Scholar
• Tan CS, Yeoh SF, Long CM. COVID-19: critical role of angiotensin 1-7 in ACE2 modulation. Ann Acad Med Singapore. 2020;49(6):398–400.
   Web of Science ®Google Scholar
• Shete A. Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19. Int J Infect Dis. 2020;96:348–351.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Liu J, Shi D, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci. 2020;16(13):2382–2391.
   PubMed Web of Science ®Google Scholar
• Tornling G, Batta R, Porter J, et al. The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 – a double-blind, randomized, placebo-controlled phase 2 trial. medRxiv Preprint; 2021.
   Google Scholar
• Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760.
   PubMed Web of Science ®Google Scholar
• Roy-Vallejo E, Sanchez Purificacion A, Torres Pena JD, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers withdrawal is associated with higher mortality in hospitalized patients with COVID-19. J Clin Med. 2021 Jun 15;10(12):2642.
   Web of Science ®Google Scholar
• Dioh W, Chabane M, Tourette C, et al. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):42.
   Web of Science ®Google Scholar
• Song GXX, Zhang K, Yu R, et al. Protective effect of 20-hydroxyecdysterone against lipopolysaccharides-induced acute lung injury in mice. J Pharm Drug Res. 2019;2(3):109–114.
   Google Scholar
• Orie NN, Raees A, Maneera YA, et al. 20-Hydroxyecdysone dilates muscle arterioles in a nitric oxide-dependent, estrogen ER-β receptor-independent manner. Phytomed Plus. 2021;1(3):100078. https://doi.org/https://doi.org/10.1016/j.phyplu.2021.100078
   Google Scholar
• Lafont R, Reynal S, Serova M, et al. 20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor. BioRxiv; 2020.
   Google Scholar